Literature DB >> 27116532

Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review.

F C Fierz1, F Meier1, K Chaloupka1, C Böni1.   

Abstract

Background. In advanced cutaneous melanoma, new systemic therapies include immunotherapy by checkpoint inhibition and targeted inhibition of the mitogen-activated protein kinase pathway; these are becoming increasingly well established. We describe the clinical presentation of uveitis in three patients with concomitant systemic melanoma treatment. History and Signs. Three patients with metastatic melanoma receiving systemic therapy (ipilimumab, vemurafenib) presented at our institution with a short history of ocular symptoms. Clinical findings included anterior uveitis, intermediate uveitis, disc swelling, inflammatory choroidal lesions and retinal vasculitis. Therapy and Outcome. All three patients responded well to local and/or systemic steroid treatment. In one case, the systemic anti-cancer drug was discontinued after the onset of uveitis. Conclusions. Ocular inflammation may occur in the setting of systemic melanoma therapy. Presentations of uveitis include Vogt-Koyanagi-Harada-like syndromes. Ocular inflammation can usually be controlled by topical and sometimes systemic corticosteroid therapy. However, treatment guidelines are not established and management of these patients demands close cooperation with the oncologist. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27116532     DOI: 10.1055/s-0042-102668

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  12 in total

1.  Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report.

Authors:  Daniel Russell Richardson; Brian Ellis; Inderjit Mehmi; Monique Leys
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

2.  Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity.

Authors:  Aditya Rali; Ye Huang; Steven Yeh
Journal:  Int Ophthalmol Clin       Date:  2022-06-22

3.  Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma.

Authors:  Niels J Brouwer; John B A G Haanen; Martine J Jager
Journal:  Ocul Oncol Pathol       Date:  2017-02-02

4.  Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.

Authors:  Suthee Rapisuwon; Benjamin Izar; Cory Batenchuk; Alexandre Avila; Shaolin Mei; Peter Sorger; Jerry M Parks; Sarah J Cooper; David Wagner; Jay C Zeck; Aline J Charabaty; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2019-03-04       Impact factor: 13.751

5.  Bilateral uveitis and macular edema induced by Nivolumab: a case report.

Authors:  Claire Theillac; Morgane Straub; Anne-Laure Breton; Luc Thomas; Stéphane Dalle
Journal:  BMC Ophthalmol       Date:  2017-12-01       Impact factor: 2.209

6.  A Rare Cause of Uveitis: Vemurafenib

Authors:  Selçuk Sızmaz; Nuhkan Görkemli; Ebru Esen; Nihal Demircan
Journal:  Turk J Ophthalmol       Date:  2018-12-27

7.  Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy.

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Meifen Zhang; Li Zhang
Journal:  Thorac Cancer       Date:  2020-02-04       Impact factor: 3.500

Review 8.  [Clinical Diagnosis and Treatment Recommendations for Ocular Toxicities of Target Therapy and Immune Checkpoint Inhibitor Therapy].

Authors:  Xiaowei Liu; Zheng Wang; Chan Zhao; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Xiaoyan Si; Li Zhang; Yue Li; Mengzhao Wang; Juhong Shi; Meifen Zhang; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20

9.  Immune checkpoint inhibitor associated ocular hypertension (from presumed trabeculitis).

Authors:  Julia Canestraro; Anna Do; Seth D Potash; Joseph Panarelli; Meghan Berkenstock; David H Abramson; Jasmine H Francis
Journal:  Am J Ophthalmol Case Rep       Date:  2021-05-24

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.